Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

That study established the company’s Astellas-partnered Nectin-4 ADC Padcev and Merck & Co.’s PD-1 king Keytruda as the ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...